Promentis Pharmaceuticals Inc. of Milwaukee, which is developing compounds for treating schizophrenia and other central nervous system disorders, has attracted $2.9 million in a second round of capital-raising. Read the full Milwaukee Business Journal story here.
Featured News
- InsideWis: Young companies leading the way on clean technologiesApril 22, 2021
- Unicorns are real! Founder of $1-billion company to speak June 3 at Entrepreneurs’ ConferenceApril 21, 2021
- Madison.com: Local health and biotech companies fighting COVID-19 for more than a yearApril 21, 2021
- WisconsinINNO: The battle for tech talent is heating up. Milwaukee is among the hotspotsApril 21, 2021
- WisBusiness: Foxconn is confident a new agreement with Wisconsin will attract other businesses to the stateApril 21, 2021